title: Endocrinological late effects after chemotherapy for testicular cancer.
abstract: Type and extent of endocrinological alterations were studied in long-term disease-free survivors after cisplatin-based chemotherapy for testicular cancer. A total of 63 patients with a median age of 30 (19-53) years, and median follow-up of 42 (16-128) months were included. Elevated serum follicle-stimulating hormone (FSH) levels were found in 63% of patients, 24% showed pathologically elevated luteinising hormone (LH) levels with normal and 10% with subnormal testosterone levels. The degree of gonadotropin elevation was highly significantly correlated with the cumulative platinum (P) dose. Patients treated with platinum-vinblastine-bleomycin regimens showed higher gonadotropin levels than those treated with platinum-etoposide-bleomycin. The adrenal androgen dehydroepiandrosterone (DHEA), pathologically elevated in 68% of patients, was significantly correlated with the cumulative doses of chemotherapy (ctx) used and to the gonadotropin levels. Treatment variables, such as type and dose of cytotoxic agents used, as well as degree of gonadotropin elevation were further correlated with changes in oestron, testosterone and 17 alpha-OH-progesterone levels. Cholesterol levels were elevated in 32% of patients and significant interactions between the steroid hormone levels and cardiovascular risk factors could be shown.
authors.affiliation: Division of Haematology/Oncology, Hannover University Medical School, Germany.
authors.forename: C C
authors.initials: CC
authors.lastname: Berger
authors.forename: C
authors.initials: C
authors.lastname: Bokemeyer
authors.forename: F
authors.initials: F
authors.lastname: Schuppert
authors.forename: H J
authors.initials: HJ
authors.lastname: Schmoll
mesh_terms: D019326:17-alpha-Hydroxyprogesterone; D000328:Adult; D000728:Androgens / Q000097:blood*; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use*; D001761:Bleomycin; D002784:Cholesterol / Q000097:blood; D002945:Cisplatin / Q000627:therapeutic use*; D013196:Dihydrotestosterone / Q000097:blood; D018572:Disease-Free Survival; D004967:Estrogens / Q000097:blood*; D005047:Etoposide; D005640:Follicle Stimulating Hormone / Q000097:blood*; D005500:Follow-Up Studies; D006801:Humans; D006908:Hydroxyprogesterones / Q000097:blood; D007986:Luteinizing Hormone / Q000097:blood*; D008297:Male; D008875:Middle Aged; D009367:Neoplasm Staging; D009919:Orchiectomy; D013736:Testicular Neoplasms / Q000097:blood* / Q000188:drug therapy* / Q000532:radiotherapy / Q000601:surgery; D013739:Testosterone / Q000097:blood; D013997:Time Factors; D014747:Vinblastine
chemical_list: D000728:Androgens; D004967:Estrogens; D006908:Hydroxyprogesterones; D013196:Dihydrotestosterone; D001761:Bleomycin; D013739:Testosterone; D014747:Vinblastine; D019326:17-alpha-Hydroxyprogesterone; D005047:Etoposide; D007986:Luteinizing Hormone; D005640:Follicle Stimulating Hormone; D002784:Cholesterol; D002945:Cisplatin